Dec. 11, 2019 06:30 UTC
PARIS--(BUSINESS WIRE)-- Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210006078/en/
Figure 1. LHON Natural History from Interim Analysis of REALITY vs. Time Course of Visual Acuity from REVERSE and RESCUE - Note: BCVA = best-corrected visual acuity. The LOWESS line for REALITY (n=15 subjects) is based on a series of polynomial regressions around each data point. The regressions use a limited look back and look forward and give distant points less weight. The time course of BCVA for REVERSE and RESCUE uses the least-squares mean based on a mixed model ANCOVA analysis. The starting points of the curves are set to the average time from onset to time of treatment (16 weeks for RESCUE, 39 weeks for REVERSE). (Photo: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported results from the REALITY registry study and an analysis of REVERSE and RESCUE Phase III data, which further highlight the poor prognosis for patients with loss of vision due to Leber Hereditary Optic Neuropathy (LHON) associated with the ND4 mutation. The results confirm LHON experts observations from their clinical practice and contrast sharply against the bilateral improvement observed in LUMEVOQ (GS010)s Phase III studies.
Natural history studies in LHON have been difficult to conduct, so these results add to the body of knowledge and firm up the conventional wisdom that with rare exceptions, LHON is marked by precipitous loss of vision with little chance of improvement in the first few years, commented Mark Moster, MD, Neuro-Ophthalmology, Wills Eye Hospital and Professor of Neurology and Ophthalmology at Thomas Jefferson University, Philadelphia, United-States, and investigator in the REVERSE and RESCUE trials. The lack of improvement in the REALITY subjects is in stark contrast to the improvements seen in our REVERSE and RESCUE patients.
REALITY is a retrospective and cross-sectional observational study of subjects with LHON, conducted in centers across Spain, Italy, France, United Kingdom, and the United States. The objective is to generate insights about the natural history of the disease based on an approach that would facilitate comparisons with REVERSE and RESCUE. The study seeks to enroll 50 subjects by the second quarter of 2020.
Interim analysis of REALITY, based on the fifteen subjects with the ND4 mutation who were at least 15 years old at onset and who had enrolled in the study as of September 2019, shows the dramatic and usually irreversible decline in visual acuity that is the typical outcome for ND4 LHON patients. Unlike in subjects enrolled in REVERSE and RESCUE, who all received a unilateral injection of LUMEVOQ, mean visual acuity in REALITY subjects did not recover after the initial decline.
These findings highlight just how remarkable the visual trends in REVERSE and RESCUE are, commented Bernard Gilly, Co-founder and Chief Executive Officer of GenSight. The findings will support our effort to provide regulatory authorities with the most robust insights about the natural history of the disease, so that we can convincingly demonstrate the therapeutic benefit delivered by LUMEVOQ.
A second set of results, derived from a pooled dataset of baseline readings from the REVERSE and RESCUE patient populations, shows that eyes farther along the progression of the disease, as measured by time since onset, had worse visual acuity.
The picture of visual decline is based on cross-sectional data, yet remains consistent with the pattern revealed by the interim analysis for REALITY.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
About LUMEVOQ (GS010)
LUMEVOQ (GS010) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. LUMEVOQ was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018.
About Leber Hereditary Optic Neuropathy (LHON)
Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of patients have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. The estimated incidence of LHON is approximately 1,400 to 1,500 new patients who lose their sight every year in the United States and Europe.
About RESCUE and REVERSE
RESCUE and REVERSE are two separate randomized, double-masked, sham-controlled Phase III trials designed to evaluate the efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in subjects affected by LHON due to the G11778A mutation in the mitochondrial ND4 gene.
The primary endpoint will measure the difference in efficacy of GS010 in treated eyes compared to sham-treated eyes based on BestCorrected Visual Acuity (BCVA), as measured with the ETDRS at 48 weeks post-injection. The patients LogMAR (Logarithm of the Minimal Angle of Resolution) scores, which are derived from the number of letters patients read on the ETDRS chart, will be used for statistical purposes. Both trials have been adequately powered to evaluate a clinically relevant difference of at least 15 ETDRS letters between treated and untreated eyes adjusted to baseline.
The secondary endpoints will involve the application of the primary analysis to bestseeing eyes that received GS010 compared to those receiving sham, and to worseseeing eyes that received GS010 compared to those that received sham. Additionally, a categorical evaluation with a responder analysis will be evaluated, including the proportion of patients who maintain vision (< ETDRS 15L loss), the proportion of patients who gain 15 ETDRS letters from baseline and the proportion of patients with Snellen acuity of >20/200. Complementary vision metrics will include automated visual fields, optical coherence tomography, and color and contrast sensitivity, in addition to quality of life scales, biodissemination and the time course of immune response. Readouts for these endpoints are at 48, 72 and 96 weeks after injection.
The trials are conducted in parallel, in 37 subjects for REVERSE and 39 subjects for RESCUE, in 7 centers across the United States, the UK, France, Germany and Italy. Week 96 results were reported in 2019 for both trials, after which patients were transferred to a long-term follow-up study that will last for three years.
ClinicalTrials.gov Identifiers: REVERSE: NCT02652780RESCUE: NCT02652767
About REFLECT
REFLECT is a multi-center, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of bilateral injections of GS010 in subjects with LHON due to the NADH dehydrogenase 4 (ND4) mutation.
The trial planned to enroll 90 patients with vision loss up to 1 year in duration and will be conducted in multiple centers in Europe and in the US.
In the active arm, GS010 will be administered as a single intravitreal injection to both eyes of each subject. In the placebo arm, GS010 will be administered as a single intravitreal injection to the first affected eye, while the fellow eye will receive a placebo injection.
The primary endpoint for the REFLECT trial is the BCVA reported in LogMAR at 1.5-Year post-treatment in the secondaffected/notyetaffected eye. The change from baseline in secondaffected/notyetaffected eyes receiving GS010 and placebo will be the primary response of interest. The secondary efficacy endpoints include: BCVA reported in LogMAR at 2-Years post-treatment in the secondaffected/notyetaffected eye compared to both placebo and the firstaffected eye receiving GS010, OCT and contrast sensitivity and quality of life scales. The first subject was treated in March 2018, and enrolment was completed in July 2019, ahead of schedule.
ClinicalTrials.gov Identifiers: REFLECT: NCT03293524
About REALITY
REALITY is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on subjects medical charts and the administration of surveys on Health-Related Quality of Life (HRQoL) and direct and indirect costs associated with the disease.
The study will recruit at least 50 subjects (both adult and pediatric) chiefly in the following countries: Spain, Italy, France, United Kingdom, and the United States.
The primary objectives for the REALITY study are: to describe the evolution of visual functional and structural changes and other associated symptoms in patients with LHON; understand the impact of LHON-related vision loss on the HRQoL; and understand the economic burden for patients and their families arising from direct and indirect costs associated with the disease. The secondary objective is to describe the relationship between genetic, lifestyle and/or environmental factors and the expression of the LHON phenotype.
The first subject was enrolled on 3 January 2018, and enrollment is targeted to be completed in early Q2 2020.
ClinicalTrials.gov Identifiers: REALITY LHON Registry: NCT03295071
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210006078/en/
- Blurred vision is a symptom of Diabetes and other conditions - Evesham Journal - May 14th, 2024
- Undiagnosed vision disorder causes reading problems in kids - WPEC - May 14th, 2024
- Here's How to Get Affordable Eye Exams and Glasses Without Insurance - CNET - May 14th, 2024
- Blurred vision is a symptom of Diabetes and other conditions - South Wales Argus - May 14th, 2024
- Could my glasses be making my eyesight worse? - The Conversation - April 8th, 2024
- Eyeglasses Improve Income as Well as Sight, Study Shows - The New York Times - April 8th, 2024
- John Berger Lost His Eyesight to Cataracts and Learned to See - Hyperallergic - April 8th, 2024
- Eye Health Facts: What You Need to Know About the Eyes - Prevention Magazine - April 8th, 2024
- Reading glasses are good for your eyes and your income : Goats and Soda - NPR - April 8th, 2024
- 'The sight to fight:' Yorktown military members make thousands of glasses for the service - News 3 WTKR Norfolk - April 8th, 2024
- How to Watch the Solar Eclipse Without Damaging Your Eyes - Verywell Health - April 8th, 2024
- Protect Your Eyes While Watching the Solar EclipseExpert Advice from NYU Langone's Dr. Nitish Mehta - NYU Langone Health - April 8th, 2024
- 10 Daily Habits That Will Help You Protect Your Eye Health - CNET - January 25th, 2024
- Undergoing cataract surgery when it's not necessary? Some do it to improve their eyesight, but it's not without risk - The Conversation Indonesia - January 25th, 2024
- Sight Care Reviews - Is It Safe to Use? The Most Important Fact to Know Before Buy! - Kent Reporter - January 25th, 2024
- Apple has big and cartoonish plans for Vision Pro's EyeSight - AppleInsider - January 25th, 2024
- National Center for Children's Vision and Eye Health at Prevent Blindness Celebrates 15th Anniversary in 2024 - PR Web - January 25th, 2024
- Understanding Computer Vision Syndrome: Causes, Symptoms, and Practical Solutions - Medriva - January 25th, 2024
- 8 Eye Issues You Should Never Ignore - Right as Rain by UW Medicine - January 9th, 2024
- Digital eye strain is a growing issue as the muscles of the eyes work overtime, warn vision experts - Fox News - January 9th, 2024
- Know the Facts About Glaucoma - MedicineNet - January 9th, 2024
- New Year, New Vision: Top Resolutions For Optimal Eye Health - ABP Live - January 9th, 2024
- Childhood Myopia and Its Impact on Vision Loss: What Causes It? - News18 - January 9th, 2024
- What you see first in optical illusion can reveal a lot about you but youll need 20/20 vision to spot hi... - The Sun - January 9th, 2024
- The Importance of Eye Care: Preventing Vision Impairments and Maintaining Good Eye Health - Medriva - December 30th, 2023
- Six ways to look after your eyes in 2024 - The Conversation - December 30th, 2023
- 6 Essential Ways to Safeguard and Improve Your Vision in 2024 - Medriva - December 30th, 2023
- SightCare Reviews - Obvious Hoax or Safe Pills That Work? Fake Scams to Avoid | Courier-Herald - Enumclaw Courier-Herald - December 30th, 2023
- SightCare Reviews - Honest Customer Warning! Real Eyesight Support or Fake Hype? - Bothell-Kenmore Reporter - December 30th, 2023
- Global Intraocular Lens Market Surges with Innovations in Vision Correction | CAGR of 5.6% - PharmiWeb.com - December 30th, 2023
- Infection of the eye, and how to protect vision - The Hindu - December 30th, 2023
- Optical Illusion Eye Test: Can you find the dog in the street in 7 seconds? - Jagran Josh - December 30th, 2023
- You have 20/20 vision if you can find the hidden chick amongst these ducks - IndiaTimes - December 30th, 2023
- Eye Doc: Look *Here* While You Drive + 8 More Genius Tips to Improve Night Vision Behind The Wheel - Yahoo Life - December 22nd, 2023
- Designer creates inclusive clothing company after losing eyesight - Fox Business - December 22nd, 2023
- What is the state of American eyesight? - USAFacts - December 22nd, 2023
- When temporary vision loss in one eye isn't a sign of stroke - Harvard Health - December 22nd, 2023
- 10 Hacks That Can Naturally Boost Your Eye Health Today - CNET - December 22nd, 2023
- SightCare Reviews (Critical Customer Warning!) Know The Sight Care Facts Before Buy - Ukiah Daily Journal - December 22nd, 2023
- Everyone can spot the building with the hole in it but only those with 20/20 vision can find the giant C... - The US Sun - December 22nd, 2023
- Flashes, shimmers and blind spots: Here's what migraine aura looks like - The Washington Post - December 22nd, 2023
- Doctors Reveal the Snack That Cuts Your Risk of Vision-Clouding Cataracts in Half - Yahoo Life - December 22nd, 2023
- Yoga For Healthy Vision: 5 Extraordinary Yogasanas To Improve Eyesight - Netmeds.com - December 22nd, 2023
- Everyone can spot the teddy bears but you have 20/20 vision if you can see the bee in the bedroom in under... - The US Sun - December 22nd, 2023
- Reindeers blue eyes act as night vision goggles to help them find food in winter - The Guardian - December 22nd, 2023
- 6 Bad Habits That Could Be Damaging Your Eyesight - Money Talks News - December 22nd, 2023
- Reindeer vision may have evolved to spot favorite food in the snowy dark of winter - Phys.org - December 22nd, 2023
- Human eyes: How they work, and their amazing anatomy - BBC Science Focus Magazine - December 22nd, 2023
- Why reindeer eyes shine blue in the winter - The Washington Post - December 22nd, 2023
- Can Everyone Unfocus Their Eyes On Command? - IFLScience - December 22nd, 2023
- You have the eyes of a hunter if you can spot the dogs owner in the picture in 8 seconds! - Jagran Josh - December 22nd, 2023
- Everyone can see the Christmas trees but you could have 20/20 vision if you can spot the star hiding in t... - The US Sun - December 22nd, 2023
- Here's how eye exams can reveal several health conditions beyond your sight - The Record (New Westminster) - December 22nd, 2023
- At Bread for the Citys vision clinic, patients can see clearly now - The Washington Post - December 13th, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or Scam (2024) | Vashon-Maury Island Beachcomber - Vashon-Maury Island Beachcomber - December 13th, 2023
- The Benefits of Donning Prescription Sunglasses for Vision Correction and Protection - Anti Aging News - December 13th, 2023
- Vision Pro training of Apple retail store employees to start soon - BGR - December 13th, 2023
- 6 Best Vitamins and Supplements for Healthy Eyes - CNET - December 13th, 2023
- Eye Health: How to Protect Eyes From Digital Strain, Vision Loss and More? 5 Tips - India.com - December 13th, 2023
- How to watch the solar eclipse without damaging your eyesight - WATE 6 On Your Side - October 16th, 2023
- Can Optical Illusions Improve Vision? Know The Best One That Benefits Eyesight - Times Now - May 17th, 2023
- Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones - April 15th, 2023
- Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference - April 15th, 2023
- GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update - April 15th, 2023
- Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow - April 15th, 2023
- Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting - April 15th, 2023
- Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference - April 15th, 2023
- Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023 - April 15th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15th, 2023
- Alvotech Provides Regulatory Update on AVT02 Biologics License Application - April 15th, 2023
- Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 - April 15th, 2023
- Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China - April 15th, 2023
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting - April 15th, 2023
- QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023 - April 15th, 2023
- ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein - April 15th, 2023
- International Carrot Day: From healthy eyesight to weight loss - 5 wonderful benefits of carrot - Zee Business - April 7th, 2023
- How the Human Eye Works | Cornea Layers/Role | Light Rays - NKCF.org - December 11th, 2022
- Eye Emergencies: Types, Symptoms, and Prevention - Healthline - November 25th, 2022
- The criteria for certification | RNIB - November 25th, 2022